Advertisement

Breast Cancer Research and Treatment

, Volume 175, Issue 3, pp 585–594 | Cite as

Explaining variation in quality of breast cancer care and its impact: a nationwide population-based study from Slovenia

  • Gaber PlavcEmail author
  • Ivica Ratoša
  • Tina Žagar
  • Vesna Zadnik
Clinical trial

Abstract

Purpose

To assess and explain variation in quality of care in breast cancer patients and estimate its impact on disease outcome.

Methods

The Slovenian National Cancer Registry database and clinical records of 1053 women with unilateral primarily non-metastatic invasive breast cancer diagnosed in 2013 were reviewed in this retrospective analysis. Quality care was defined as care fully compliant with quality indicators (QI) defined by European Society of Breast Cancer Specialists (EUSOMA). Multivariate logistic regression was used to determine the predictors of receiving quality care. Differences in overall survival (OS) and event-free survival (EFS, relapse, or progression of disease or death considered an event) based on adherence to QI were analyzed using Kaplan–Meier method and Cox models.

Results

Younger age, no comorbidities, and HER2-negative tumor were associated with increased odds ratios for receiving quality care, whereas tumor stage and type of hospital had no significant association. Median follow-up was 54.5 months. Not receiving quality care resulted in an increased risk of dying [hazard ratio (HR) 1.68; 95% confidence interval (CI) 1.06–2.66; p = 0.026]. Difference in EFS between two groups was significant after adjusting for case mix and type of hospital (HR 1.80; 95% CI 1.29–2.52; p = 0.001) but disappeared when type of treatment was added into the model (HR 1.30; 95% CI 0.89–1.90; p = 0.178).

Conclusion

Observed comorbidity and age bias in delivering quality breast cancer care could be medically justifiable, whereas observed deviations dependent on HER2 status are puzzling. Complete adherence of treatment to quality indicators resulted in better OS.

Keywords

Breast neoplasm Quality indicators EUSOMA Health services Survival 

Notes

Acknowledgements

We would like to thank Andraž Perhavec, MD, PhD, for a critical review of the article.

Funding

The work was supported in part by ERA-NET within the framework of the call on “Translational research on tertiary prevention in cancer patients” (TRANSCAN), with funding from Ministry of Education, Science and Sport (MIZS), Slovenia.

Compliance with ethical standards

Conflict of interest

The authors declare no further conflicts of interest.

Ethical approval

The study protocol was approved by the Protocol Review Board and Ethics Committee of the Institute of Oncology Ljubljana.

Informed consent

Informed consent for using their data for retrospective study purposes at the start of their treatment was obtained from all individual participants included in the study.

References

  1. 1.
    Vardy J, Tannock IF (2004) Quality of cancer care. Ann Oncol 15:1001–1006CrossRefGoogle Scholar
  2. 2.
    Hillner BE, Smith TJ, Desch CE (2000) Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 18:2327–2340CrossRefGoogle Scholar
  3. 3.
    Erickson BK, Martin JY, Shah MM, Straughn JM, Leath CA (2014) Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol 133:142–146CrossRefGoogle Scholar
  4. 4.
    Hines RB, Barrett A, Twumasi-Ankrah P, Broccoli D, Engelman KK, Baranda J et al (2015) Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. J Natl Compr Cancer Netw 13:51–60CrossRefGoogle Scholar
  5. 5.
    Vrijens F, Stordeur S, Beirens K, Devriese S, Van Eycken E, Vlayen J (2012) Effect of hospital volume on processes of care and 5-year survival after breast cancer: a population-based study on 25,000 women. Breast 21:261–266CrossRefGoogle Scholar
  6. 6.
    Hebert-croteau N, Brisson J, Pineault R (2000) Review of organizational factors related to care offered to women with breast cancer. Public Health 22:45–55Google Scholar
  7. 7.
    Lebeau M, Mathoulin-Pelissier S, Bellera C, Tunon-de-Lara C, Daban A, Lipinski F et al (2011) Breast cancer care compared with clinical Guidelines: an observational study in France. BMC Public Health 11:45CrossRefGoogle Scholar
  8. 8.
    Cheng SH, Wang CJ, Lin JL, Horng CF, Lu MC, Asch SM et al (2009) Adherence to quality indicators and survival in patients with breast cancer. Med Care 47:217–225CrossRefGoogle Scholar
  9. 9.
    Andreano A, Rebora P, Valsecchi MG, Russo AG (2017) Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach. Breast Cancer Res Treat 164:119–131CrossRefGoogle Scholar
  10. 10.
    Kuo RN, Chung KP, Lai MS (2013) Re-examining the significance of surgical volume to breast cancer survival and recurrence versus process quality of care in Taiwan. Health Serv Res 48:26–46CrossRefGoogle Scholar
  11. 11.
    Jacke CO, Albert US, Kalder M (2015) The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients. BMC Cancer 15:1–11CrossRefGoogle Scholar
  12. 12.
    Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T (2017) Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 22:47–55CrossRefGoogle Scholar
  13. 13.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefGoogle Scholar
  14. 14.
    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223CrossRefGoogle Scholar
  15. 15.
    Rosselli Del Turco M, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B et al (2010) Quality indicators in breast cancer care. Eur J Cancer 46:2344–2356CrossRefGoogle Scholar
  16. 16.
    Žgajnar J (2011) Prenovljene smernice zdravljenja raka dojk (in Slovene). Onkologija 15:36Google Scholar
  17. 17.
    Kiderlen M, Ponti A, Tomatis M, Boelens PG, Bastiaannet E, Wilson R et al (2015) Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: a European Society of Breast Cancer Specialists database analysis. Eur J Cancer 51:1221–1230CrossRefGoogle Scholar
  18. 18.
    Bloom BS, De Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D (2004) Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer 90:26–30CrossRefGoogle Scholar
  19. 19.
    Wyld L, Garg DK, Kumar ID, Brown H, Reed MWR (2004) Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 90:1486–1491CrossRefGoogle Scholar
  20. 20.
    Hébert-Croteau N, Roberge D, Brisson J (2007) Provider’s volume and quality of breast cancer detection and treatment. Breast Cancer Res Treat 105:117–132CrossRefGoogle Scholar
  21. 21.
    Yen TWF, Pezzin LE, Li J, Sparapani R, Laud PW, Nattinger AB (2017) Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study. Cancer 123:957–966CrossRefGoogle Scholar
  22. 22.
    Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44:992–999CrossRefGoogle Scholar
  23. 23.
    Hébert-Croteau N, Brisson J, Lemaire J, Latreille J, Pineault R (2005) Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer. Cancer 104:1343–1348CrossRefGoogle Scholar
  24. 24.
    Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16:266–273CrossRefGoogle Scholar
  25. 25.
    Biganzoli L, Marotti L, Hart CD, Cataliotti L, Cutuli B, Kühn T et al (2017) Quality indicators in breast cancer care: an update from the EUSOMA working group. Eur J Cancer 86:59–81CrossRefGoogle Scholar
  26. 26.
    Inwald EC, Ortmann O, Zeman F, Koller M, Hofstädter F, Gerstenhauer M et al (2014) Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed Res Int 2014:1–10CrossRefGoogle Scholar
  27. 27.
    Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K et al (2010) Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 78:189–195CrossRefGoogle Scholar
  28. 28.
    Wöckel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M et al (2010) Effects of guideline adherence in primary breast cancer-a 5-year multi-center cohort study of 3976 patients. Breast 19:120–127CrossRefGoogle Scholar
  29. 29.
    Donabedian A (1966) Evaluating the quality of medical care. Milbank Q 44:166–203CrossRefGoogle Scholar
  30. 30.
    Brook RH, McGlynn EA, Cleary PD (1996) Quality of health care. Part 2: measuring quality of care. N Engl J Med 335:966–970CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyInstitute of Oncology LjubljanaLjubljanaSlovenia
  2. 2.Department of Epidemiology and Cancer RegistryInstitute of Oncology LjubljanaLjubljanaSlovenia

Personalised recommendations